Prices Could Be Slashed Under U.K.’s New Drug-Pricing Scheme
This article was originally published in The Pink Sheet Daily
Executive Summary
Prices may decrease, but at least wider societal benefits are to be included in NICE’s assessment in the U.K.’s new value-based pricing (VBP) scheme for new pharmaceuticals, a change long demanded by critics of the health technology assessment body.